Periodontal disease treatment seems to have a beneficial effect in controlling disease activity in SLE patients under immunosuppressive therapy and therefore, management of this modifiable risk factor is recommended. PubMed, Clin Rheumatol, 2014 Jan 11. (Also see: Systemic Lupus Erythematosus Treatments and Immunosuppressants)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.